Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: A metaanalysis

Clinical Breast Cancer

Volumn 7, Issue 5, 2006, Pages 372-379

  Lyman, Gary H ^a   Kuderer, Nicole M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Diagnostic odds ratio; Likelihood ratio; Predictive value; Sensitivity; Specificity

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; META ANALYSIS; MICROARRAY ANALYSIS; PREDICTION; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; VALIDATION PROCESS;

EID: 33846479370     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.053     Document Type: Article

References (35)

1. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 1998; 52:289-303.
2. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990; 6:5-30.
3. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Brit Med J 2003; 327:557-560.
4. DerSimonian R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
5. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-536.
6. Van De Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009.
7. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Can Inst 2006; 98:1183-1192.
8. Espinosa E, Vara JAF, Redondo A, et al. Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase rasechain reaction study. J Clin Oncol 2005; 23:7278-7285.
9. Ahr A, Karn T, Solbach C, et al. Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002; 359:131-132.
10. Bertucci F, Nasser V, Granjeaud S, et al. Gene expression profiles of poor prognosis primary breast cancer correlate with survival. Hum Mol Genet 2002; 11:863-872.
11. Huang E, Cheng SH, Dressman H, et al. Gene expression predictors of breast cancer outcomes. Lancet 2003; 361:1590-1596.
12. Iwao K, Matoba R, Ueno N, et al. Molecular classification of primary breast tumors possessing distinct prognostic properties. Hum Mol Genet 2002; 11:199-206.
13. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node negative breast cancer. N Engl J Med 2004; 351:2817-2826.
14. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 23:3726-3734.
15. Esteva FJ, Sahin AA, Coombes L, et al. Multi-gene RT-PCR assay for predicting recurrence in node-negative breast cancer patients that did not receive adjuvant tamoxifen nor chemotherapy. Breast Cancer Res Treat 2004; 88(suppl 1):1-253.
16. Esteva FJ, Sahin AA, Cristofanilli M, et al. Prognostic role of a multi-gene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 2005; 11:3315-3319.
17. Wang Y, Klijn JGM, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node negative primary breast cancer. Lancet 2005; 365:671-679.
18. Foekens JA, Atkins D, Zhang Y, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006; 24:1665-1671.
19. Pawitan Y, Bjohle J, Amler L, et al. Gene expression profiling spares early stage breast cancer patients from adjuvant therapy: derived and validated in two population based cohorts. Breast Cancer Res 2005; 7:R953-R964.
20. Simon R, Radmacher MD, Dobbin K, et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Caner Inst 2003; 95:14-18.
21. Ntzani EE, Ioannidis JPA. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 2003; 362:1439-1444.
22. Simon R. Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Brit J Cancer 2003; 89:1599-1604.
23. Deeks JJ. Systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001; 323:157-162.
24. Vamvakas E. Meta-analysis of studies of the diagnostic accuracy of laboratory tests: a review of the concepts and methods. Arch Pathol Lab Med 1998; 122:675-686.
25. Irwig L, Tosteson ANA, Gatsonis C, et al. Guidelines for meta-analysis evaluating diagnostic tests. Ann Intern Med 1994; 120:667-676.
26. Shepes SB, Schechter MT. The assessment of diagnostic tests. JAMA 1984; 252:2418-2422.
27. Vamvakas E. Meta-analysis of studies of the diagnostic accuracy of laboratory tests: a review of the concepts and methods. Arch Pathol Lab Med 1998; 122:675-686.
28. Lijmer JG, Mol BW, Heisterkamp S, et al. Empirical evidence of design related bias in studies of diagnostic tests. J Am Med Assoc 1999; 282:1061-1066.
29. Lyman GH, Djulbegovic B. The challenge of systematic reviews in cancer screening, diagnostic and staging studies. Cancer Treat Rev 2005; 31:628-639.
30. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph node negative, estrogen receptor positive, early-stage breast cancer [published erratum in Am J Managed Care 2005; 11:476]. Am J Managed Care 2005; 11:313-324.
31. Lyman GH, Cosler LE, Hornberger J. A 21-gene RT-PCR assay in lymph node -, estrogen receptor +, early-stage breast cancer: an age-specific economic analysis. Breast Cancer Res Treat 2004; 88(suppl 1): S103 (Abstract #2081).
32. Lyman GH, Kuderer NM. Gene expression profile signatures to predict survival in diffuse large B-cell lymphoma: a meta-analysis of early results. Blood 2004; 104:241 (Abstract #2274).
33. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365:488-492.
34. Chang JC, Hilsenbeck SG, Fuqua SAW. Genomic approaches in the management and treatment of breast cancer. Brit J Cancer 2005; 92:618-624.
35. Lyman GH, Kuderer NM. The strengths and limitations of meta-analyses based on aggregate patient data. BMC Med Res Methodol 2005; 5:14.